Precigen, Inc. EV/FCF

EV/FCF of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of Precigen, Inc. is -13.61 (as of December 31, 2021)
  • EV/FCF for the quarter ending March 31, 2022 was -8.07 (a -40.72% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -66.35%
  • Annual EV/FCF for 2021 was -13.61 (a -40.16% decrease from previous year)
  • Annual EV/FCF for 2020 was -22.75 (a 298.76% increase from previous year)
  • Annual EV/FCF for 2019 was -5.7 (a 11.71% increase from previous year)
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Precigen, Inc.

Most recent EV/FCFof PGEN including historical data for past 10 years.

Interactive Chart of EV/FCF of Precigen, Inc.

Precigen, Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -8.07
2021 -13.61 -18.98 -23.99 -22.22 -13.61
2020 -22.75 -6.52 -7.82 -4.15 -22.75
2019 -5.7 -5.46 -6.69 -4.79 -5.7
2018 -5.11 -12.42 -10.45 -11.42 -5.11
2017 -10.37 -17.21 -22.86 -20.81 -10.37
2016 -33.49 -73.18 78.56 118.33 -33.49
2015 132.46 906.25 -95.27 -96.5 132.46
2014 -100.74 -66.21 -67.77 -69.22 -100.74
2013 -14.6 -19.18 -0.22 -0.22 -14.6
2012 -0.22 -0.22 -0.22
2011 -0.22

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology